Follow FIH trial patients to gather long-term safety and efficacy evidence
Deadline not yet reached (1161 days left)
- Announced
- 19 Oct 2026
- Due
- 31 Dec 2029
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We look forward to gathering further long-term safety and efficacy evidence as we follow these patients through 2029.”
What we found
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2029.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Follow
- Deliverable
- long-term safety and efficacy evidence
- In the company’s control
- High
- Specificity
- Medium
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you SpyGlass Pharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-SGP-017668 · Corrections policy